Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
Double-blind placebo controlled study of Cannabidiol (CBD) for symptoms of PTSD in adults
using liquid structure(TM) Formulation (Nantheia ATL5(TM)). Subjects complete 3 weeks of
baseline data collection including assessments of activity and sleep. Intervention is
Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks.
Standardized symptom profile measurements, clinician assessments, laboratory testing,
collection of inflammatory biomarkers, and suicide screening is completed throughout. Age-
and gender-matched control subjects are enrolled and complete baseline data collection only.
All subjects may complete optional procedures of driving assessments and functional MRI
(fMRI).
Phase:
Phase 2
Details
Lead Sponsor:
University of Nebraska
Collaborators:
Ananda Scientific Inc University of Texas at Austin